Articles Archives

Cryoport Systems Honored at the Asia Pacific Biopharma Excellence Awards

Cryoport Systems is pleased to announce that we have been awarded Best Logistics & Supply Chain Management Supplier – Digital Technology & Software at the Asia Pacific Biopharma Excellence Awards 2026, held March 11 in Singapore. This recognition reflects both the progress of our organization and the growing importance of dependable, technology-driven support in the development and delivery of advanced therapies across the region.

Read More

Embracing Digital Excellence with Transition to Digital Shipping Instructions

Cryoport Systems is thrilled to announce the official transition from printed shipping instructions to digital, QR code-based instructions. This move strengthens our commitment to sustainability and operational excellence while providing a streamlined user experience. This change reflects a natural evolution in how life sciences organizations access and standardize critical shipping information, and we’re excited to bring these enhancements to our global client community.  

Read More

Cryoport Systems Named Finalist in Four Categories at Asia-Pacific Biopharma Excellence Awards 2026

Cryoport Systems has been named a finalist in four categories for the upcoming Asia-Pacific Biopharma Excellence Awards 2026. These nominations reflect our unwavering commitment to innovation and excellence in supporting the global biopharma community.

Read More

Cryoport Systems Wins “BioServices Innovation of the Year” for Safepak® Soft System 1800

Cryoport Systems is proud to announce that our Safepak® Soft System 1800 has been named BioServices Innovation of the Year by the prestigious BioTech Breakthrough Awards program. This recognition highlights our continued commitment to advancing cryogenic logistics for cell and gene therapy developers through innovation and excellence when it comes to safety and sustainability.

Read More

Cryoport Systems Sets New Benchmark for the Global Regenerative Medicine Supply Chain

Cryoport Systems has achieved a significant milestone by becoming the first global supply chain company worldwide to secure ISO 21973:2020 certification from the DNV Business Assurance.  This certification marks a pivotal advancement in our mission to set the highest benchmarks for safety, traceability, and product integrity in the cell and gene therapy sector and across the life sciences. 

Read More

Cryoport Systems Wins CPHI Pharma Award for Supply Chain Excellence

We are proud to announce that Cryoport Systems has been awarded the prestigious Supply Chain Excellence Award at the 2025 CPHI Pharma Awards, a recognition that celebrates innovation, impact, and leadership in pharmaceutical supply chain management. This honor reflects our unwavering commitment to transforming the way life-saving therapies are managed and delivered to patients across the globe.

Read More

Cryoport Systems Redefines the Global Supply Chain with Launch of New Facility Near Paris, France

Cryoport Systems is thrilled to announce the grand opening of our revolutionary Global Supply Chain Center in Louvre, France. This cutting-edge campus is a one-stop location for end-to-end, temperature-controlled supply chain solutions and is designed to tackle the most complex challenges in the life sciences industry.

Read More

Cryoport Systems Wins Best Cell & Gene Therapy Supplier Award at APCGTEA 2025

Cryoport Systems is proud to announce that we have been awarded Best Cell & Gene Therapy Supplier – Cell Processing Systems at the 2025 Asia-Pacific Cell & Gene Therapy Excellence Awards (APCGTEA).

Read More

A Glimpse Inside the Future of ATMP Supply Chains: Alison Pritchard on the Beyond Biotech Podcast

In an industry where innovation moves fast but patient access often lags behind, how can we build supply chains that are not only compliant and efficient, but also flexible and ready to scale?  That’s the question Alison Pritchard, Vice President of Business Development for Cryoport Systems, tackles in her recent interview with Beyond Biotech, the podcast from Labiotech.eu. Alison explores the state of the advanced therapy medicinal products (ATMP) market in 2025 and what it will take to meet the rising expectations of therapeutic developers, regulators, and – most importantly – patients. 

Read More